Amazon Plans Significant Capital Expenditure Increase
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2026
0mins
Should l Buy TECH?
Source: stocktwits
- Capital Expenditure Increase: Amazon announced in its latest earnings report that it will raise its capital expenditure for 2026 to $200 billion from approximately $130 billion in 2025, indicating strong confidence in future growth while raising investor concerns over high spending.
- Stock Price Volatility: Although Amazon shares rose 0.27% on Friday, they have declined about 17.5% over the past month and are hovering near their lowest level since May 2025, reflecting market caution regarding the company's future performance.
- Market Sentiment Shift: Retail sentiment on Stocktwits has shifted from 'extremely bullish' to 'bullish' in the past 24 hours, with a 35% increase in discussions, indicating a divergence in investor opinions about the stock's trajectory.
- Industry Investment Trends: Amazon's capital expenditure plans align with other major tech companies, which collectively plan to invest over $630 billion in AI buildouts in 2026, highlighting strong expectations for AI demand despite investor concerns about massive expenditures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TECH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TECH
Wall Street analysts forecast TECH stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 59.230
Low
60.00
Averages
66.14
High
72.00
Current: 59.230
Low
60.00
Averages
66.14
High
72.00
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bio-Techne Unveils Streamlined Brand Architecture
- Brand Architecture Optimization: Bio-Techne has announced the organization of its products and technologies into three focused portfolio brands—R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™—to simplify the product discovery process for scientists and clinicians, thereby enhancing customer experience and market competitiveness.
- Support for Scientific Discovery: The R&D Systems™ portfolio offers high-quality proteins, antibodies, and small molecules that assist researchers in generating reproducible results and advancing early-stage research towards clinical applications, further solidifying the company's leadership position in the life sciences sector.
- Advancement in Translational Research: The Bio-Techne Spatial™ portfolio leverages advanced RNAscope™ and COMET™ technologies to provide high-resolution visualization of RNA and proteins, supporting multi-omic analysis that helps researchers identify clinically relevant biomarkers and accelerate therapeutic discovery.
- Comprehensive Diagnostic Solutions: The Bio-Techne Diagnostics™ portfolio provides clinical laboratories and IVD manufacturers with a full range of diagnostic reagents and tools, supporting the entire lifecycle from early design to large-scale deployment, ensuring diagnostic accuracy and ultimately improving patient outcomes.
See More
Bio-Techne to Host Q3 Fiscal 2026 Earnings Call
- Earnings Call Announcement: Bio-Techne will host a conference call on May 6, 2026, at 8:00 a.m. CDT to review its Q3 fiscal 2026 financial results, which is expected to provide investors with critical financial data and future outlook.
- Participation Details: Investors can join the call by dialing 1-800-343-4136 or 1-203-518-9843 for international access, with Conference ID TECHQ3, ensuring global investors can stay updated on the company's latest developments.
- Replay Information: For those unable to attend the live call, Bio-Techne offers a replay service starting at 11:00 a.m. CDT on May 6, 2026, available until 11:00 p.m. CDT on June 6, 2026, allowing investors to review the meeting content at their convenience.
- Company Overview: Bio-Techne is a global life sciences company with over $1.2 billion in net sales for fiscal 2025 and approximately 3,100 employees, dedicated to providing innovative tools and bioactive reagents for research and clinical diagnostics, facilitating scientific investigations and drug discovery.
See More
Bio-Techne Expands COMET™ Portfolio with New SPYRE™ Solutions
- Product Line Expansion: Bio-Techne announced the addition of SPYRE™ Focus Panels and SPYRE™ Amplification Kits to its COMET™ solution portfolio, enhancing the modular automated spatial biology workflow's flexibility and sensitivity, enabling researchers to conduct deeper analyses of biological data.
- Technological Innovation: The newly introduced HORIZON™ Image Analysis Software is tailored for COMET hyperplex images using SPYRE tools, further streamlining tissue analysis processes and improving the efficiency and accuracy of data extraction.
- Research Support: SPYRE™ Antibody Panels and Amplification Kits leverage seqLA™ technology to significantly enhance the detection of low-abundance targets while reducing optimization time, allowing researchers to investigate tumor and microenvironment cells simultaneously within the same sample.
- Market Impact: With over $1.2 billion in net sales in fiscal 2025, Bio-Techne further solidifies its leadership position in the life sciences tools market with the launch of these new products, driving advancements in clinical diagnostics and drug discovery.
See More
Bio-Techne Launches New SPYRE™ Panels and Amplification Kits to Enhance Spatial Biology Workflows
- Product Portfolio Expansion: Bio-Techne has launched new SPYRE™ Focus Panels and Amplification Kits, enhancing the modular and automated spatial biology workflows of the COMET™ solution, which improves flexibility and sensitivity, enabling researchers to conduct deeper analyses of biological data.
- Technological Innovation: The SPYRE™ Amplification Kits utilize seqLA™ technology to significantly enhance the detection of low-abundance and challenging targets, supporting more complex tissue sample analyses and accelerating preclinical therapeutic development.
- Positive User Feedback: Professor Joanne Edwards from the University of Glasgow noted that using the pre-optimized SPYRE panels not only increased the capacity of conventional multiplex immunofluorescence but also enabled a one-day experimental protocol, highlighting the technology's importance in investigating tumor and microenvironment cells.
- Significant Market Impact: Bio-Techne generated over $1.2 billion in net sales in fiscal 2025, and with the introduction of these new products, the company is expected to further enhance its market share and competitiveness in the life sciences sector.
See More
Hollow Brook Exits Entire Position in Bio-Techne
- Complete Exit: Hollow Brook Wealth Management LLC sold its entire position in Bio-Techne, divesting 174,677 shares valued at approximately $10.7 million during Q4 2025, indicating a significant loss of confidence as the stake now accounts for 0% of its 13F AUM.
- Performance Decline: Bio-Techne's shares have dropped 12.68% over the past year, with revenue growth slowing to low single digits and flat year-over-year revenue in the most recent quarter, highlighting challenges amid sluggish spending from biopharma and biotech clients.
- Market Underperformance: The stock has lagged the broader market by nearly 34 percentage points over the past year, reflecting investor concerns about its growth prospects, particularly as demand from customers weakens, leading wealth managers to lose confidence in holding the stock.
- Future Outlook: While the exit may signal negative sentiment, Bio-Techne still boasts approximately 80% recurring revenue, and analysts have an average price target of $74, over 40% above the current share price, suggesting potential for recovery.
See More
Bio-Techne and UnitedHealth Options Trading Activity Surges
- Bio-Techne Options Volume: Bio-Techne Corp (Ticker: TECH) has seen an options trading volume of 15,116 contracts today, equating to approximately 1.5 million shares, which represents a significant 62.4% of its average daily trading volume over the past month of 2.4 million shares.
- High Volume Contracts: Notably, the $60 strike call option for TECH has recorded a high volume of 5,055 contracts traded today, representing around 505,500 underlying shares, indicating strong market interest at this price level.
- UnitedHealth Options Activity: UnitedHealth Group Inc (Ticker: UNH) has reported an options trading volume of 39,170 contracts today, translating to approximately 3.9 million shares, which is about 47.5% of its average daily trading volume over the past month of 8.3 million shares, reflecting investor focus on its future performance.
- Key Contract Insights: The $300 strike call option for UNH has seen a trading volume of 2,172 contracts today, representing approximately 217,200 shares, suggesting bullish expectations in the market, potentially linked to anticipated future earnings performance.
See More
Bio-Techne Unveils Streamlined Brand Architecture
- Brand Architecture Optimization: Bio-Techne has announced the organization of its products and technologies into three focused portfolio brands—R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™—to simplify the product discovery process for scientists and clinicians, thereby enhancing customer experience and market competitiveness.
- Support for Scientific Discovery: The R&D Systems™ portfolio offers high-quality proteins, antibodies, and small molecules that assist researchers in generating reproducible results and advancing early-stage research towards clinical applications, further solidifying the company's leadership position in the life sciences sector.
- Advancement in Translational Research: The Bio-Techne Spatial™ portfolio leverages advanced RNAscope™ and COMET™ technologies to provide high-resolution visualization of RNA and proteins, supporting multi-omic analysis that helps researchers identify clinically relevant biomarkers and accelerate therapeutic discovery.
- Comprehensive Diagnostic Solutions: The Bio-Techne Diagnostics™ portfolio provides clinical laboratories and IVD manufacturers with a full range of diagnostic reagents and tools, supporting the entire lifecycle from early design to large-scale deployment, ensuring diagnostic accuracy and ultimately improving patient outcomes.
See More
Bio-Techne to Host Q3 Fiscal 2026 Earnings Call
- Earnings Call Announcement: Bio-Techne will host a conference call on May 6, 2026, at 8:00 a.m. CDT to review its Q3 fiscal 2026 financial results, which is expected to provide investors with critical financial data and future outlook.
- Participation Details: Investors can join the call by dialing 1-800-343-4136 or 1-203-518-9843 for international access, with Conference ID TECHQ3, ensuring global investors can stay updated on the company's latest developments.
- Replay Information: For those unable to attend the live call, Bio-Techne offers a replay service starting at 11:00 a.m. CDT on May 6, 2026, available until 11:00 p.m. CDT on June 6, 2026, allowing investors to review the meeting content at their convenience.
- Company Overview: Bio-Techne is a global life sciences company with over $1.2 billion in net sales for fiscal 2025 and approximately 3,100 employees, dedicated to providing innovative tools and bioactive reagents for research and clinical diagnostics, facilitating scientific investigations and drug discovery.
See More
Bio-Techne Expands COMET™ Portfolio with New SPYRE™ Solutions
- Product Line Expansion: Bio-Techne announced the addition of SPYRE™ Focus Panels and SPYRE™ Amplification Kits to its COMET™ solution portfolio, enhancing the modular automated spatial biology workflow's flexibility and sensitivity, enabling researchers to conduct deeper analyses of biological data.
- Technological Innovation: The newly introduced HORIZON™ Image Analysis Software is tailored for COMET hyperplex images using SPYRE tools, further streamlining tissue analysis processes and improving the efficiency and accuracy of data extraction.
- Research Support: SPYRE™ Antibody Panels and Amplification Kits leverage seqLA™ technology to significantly enhance the detection of low-abundance targets while reducing optimization time, allowing researchers to investigate tumor and microenvironment cells simultaneously within the same sample.
- Market Impact: With over $1.2 billion in net sales in fiscal 2025, Bio-Techne further solidifies its leadership position in the life sciences tools market with the launch of these new products, driving advancements in clinical diagnostics and drug discovery.
See More
Bio-Techne Launches New SPYRE™ Panels and Amplification Kits to Enhance Spatial Biology Workflows
- Product Portfolio Expansion: Bio-Techne has launched new SPYRE™ Focus Panels and Amplification Kits, enhancing the modular and automated spatial biology workflows of the COMET™ solution, which improves flexibility and sensitivity, enabling researchers to conduct deeper analyses of biological data.
- Technological Innovation: The SPYRE™ Amplification Kits utilize seqLA™ technology to significantly enhance the detection of low-abundance and challenging targets, supporting more complex tissue sample analyses and accelerating preclinical therapeutic development.
- Positive User Feedback: Professor Joanne Edwards from the University of Glasgow noted that using the pre-optimized SPYRE panels not only increased the capacity of conventional multiplex immunofluorescence but also enabled a one-day experimental protocol, highlighting the technology's importance in investigating tumor and microenvironment cells.
- Significant Market Impact: Bio-Techne generated over $1.2 billion in net sales in fiscal 2025, and with the introduction of these new products, the company is expected to further enhance its market share and competitiveness in the life sciences sector.
See More
Hollow Brook Exits Entire Position in Bio-Techne
- Complete Exit: Hollow Brook Wealth Management LLC sold its entire position in Bio-Techne, divesting 174,677 shares valued at approximately $10.7 million during Q4 2025, indicating a significant loss of confidence as the stake now accounts for 0% of its 13F AUM.
- Performance Decline: Bio-Techne's shares have dropped 12.68% over the past year, with revenue growth slowing to low single digits and flat year-over-year revenue in the most recent quarter, highlighting challenges amid sluggish spending from biopharma and biotech clients.
- Market Underperformance: The stock has lagged the broader market by nearly 34 percentage points over the past year, reflecting investor concerns about its growth prospects, particularly as demand from customers weakens, leading wealth managers to lose confidence in holding the stock.
- Future Outlook: While the exit may signal negative sentiment, Bio-Techne still boasts approximately 80% recurring revenue, and analysts have an average price target of $74, over 40% above the current share price, suggesting potential for recovery.
See More
Bio-Techne and UnitedHealth Options Trading Activity Surges
- Bio-Techne Options Volume: Bio-Techne Corp (Ticker: TECH) has seen an options trading volume of 15,116 contracts today, equating to approximately 1.5 million shares, which represents a significant 62.4% of its average daily trading volume over the past month of 2.4 million shares.
- High Volume Contracts: Notably, the $60 strike call option for TECH has recorded a high volume of 5,055 contracts traded today, representing around 505,500 underlying shares, indicating strong market interest at this price level.
- UnitedHealth Options Activity: UnitedHealth Group Inc (Ticker: UNH) has reported an options trading volume of 39,170 contracts today, translating to approximately 3.9 million shares, which is about 47.5% of its average daily trading volume over the past month of 8.3 million shares, reflecting investor focus on its future performance.
- Key Contract Insights: The $300 strike call option for UNH has seen a trading volume of 2,172 contracts today, representing approximately 217,200 shares, suggesting bullish expectations in the market, potentially linked to anticipated future earnings performance.
See More
